Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q4 FY25 results · Jan–Mar 2025
Divi's Laboratories reported revenue from operations of ₹2,585.00 crore (up 12.2% from Q4 FY24) and net profit of ₹662.00 crore (up 23.0% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,585.00 | 2,303.00 | +12.2% | 2,319.00 | +11.5% |
| Other income | 86.00 | 79.00 | +8.9% | 82.00 | +4.9% |
| Total income | 2,671.00 | 2,382.00 | +12.1% | 2,401.00 | +11.2% |
| Profit before tax | 864.00 | 713.00 | +21.2% | 726.00 | +19.0% |
| Net profit for the period | 662.00 | 538.00 | +23.0% | 589.00 | +12.4% |
| EPS, basic (₹) | 24.93 | 20.25 | +23.1% | 22.20 | +12.3% |
| Net margin (%) | 25.6 | 23.4 | 25.4 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,536.00 | 2,259.00 | +12.3% | 2,297.00 | +10.4% |
| Other income | 87.00 | 79.00 | +10.1% | 82.00 | +6.1% |
| Total income | 2,623.00 | 2,338.00 | +12.2% | 2,379.00 | +10.3% |
| Profit before tax | 861.00 | 700.00 | +23.0% | 730.00 | +17.9% |
| Net profit for the period | 667.00 | 531.00 | +25.6% | 594.00 | +12.3% |
| EPS, basic (₹) | 25.12 | 19.99 | +25.7% | 22.39 | +12.2% |
| Net margin (%) | 26.3 | 23.5 | 25.9 |
Consolidated
- Filed with BSE
- 17 May 2025, 17:40 IST
- Board meeting
- 17 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2025, 17:40 IST
- Board meeting
- 17 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE